| Rotavirus vaccines: entering a new stage of deployment. | |
| | |
MedLine Citation:
|
PMID: 17762784 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE OF REVIEW: Rotavirus is the single most important cause of severe diarrhoea in infants and young children. This review provides updated information concerning three rotavirus vaccines that are being evaluated and introduced globally. RECENT FINDINGS: Two large, phase III clinical trials, each involving more than 60,000 infants in both developing and developed countries, demonstrated that both RotaTeq (Merck & Co., Whitehouse Station, New Jersey, USA), the pentavalent human-bovine reassortant vaccine, and Rotarix (GlaxoSmithKine Biologicals, Rixensart, Belgium), the monovalent live-attenuated human rotavirus vaccine, are safe with respect to intussusception when the first dose is administered between 6 and 12 weeks of age, and that both vaccines are 90-95% efficacious in preventing severe rotavirus gastroenteritis including hospitalization. The bovine (UK)-human rotavirus reassortant tetravalent (BRV-TV) vaccine, developed at the National Institutes of Health (USA), was licensed for local production in several developing countries. SUMMARY: Rotavirus vaccines are entering a new stage of deployment toward the goal of reducing morbidity and mortality attributed to rotavirus infection in developing countries, and hospitalizations and emergency visits caused by rotavirus in developed countries. High vaccine prices appear to offset cost savings, and may make policymakers even in wealthy countries hesitate to introduce a rotavirus vaccine into their childhood immunization programmes. |
| | |
Authors:
|
Osamu Nakagomi; Nigel A Cunliffe |
Related Documents
:
|
2554854 - Rotavirus serotypes causing acute diarrhoea in hospitalized children in yogyakarta, ind... 21048524 - Decline in rotavirus hospitalizations and health care visits for childhood diarrhea fol... 9935144 - Evaluation of varicella reporting to the national notifiable disease surveillance syste... 16398834 - Varicella vaccination in australia. 3051324 - Effect of pancreatic glucagon and its 1-21 fragment on gastric emptying in man. 3407494 - Using tom and huck to develop moral reasoning in adolescents: a strategy for the classr... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current opinion in infectious diseases Volume: 20 ISSN: 0951-7375 ISO Abbreviation: Curr. Opin. Infect. Dis. Publication Date: 2007 Oct |
Date Detail:
|
Created Date: 2007-08-31 Completed Date: 2007-12-10 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8809878 Medline TA: Curr Opin Infect Dis Country: United States |
Other Details:
|
Languages: eng Pagination: 501-7 Citation Subset: IM |
Affiliation:
|
Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan. onakagom@net.nagasaki-u.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cost-Benefit Analysis Diarrhea / prevention & control, virology Gastroenteritis / prevention & control, virology Humans Immunization Programs Immunization Schedule Infant Intussusception / etiology Rotavirus / classification, genetics, immunology Rotavirus Infections / prevention & control*, virology Rotavirus Vaccines* / administration & dosage, adverse effects, economics, immunology |
| Chemical | |
Reg. No./Substance:
|
0/Rotavirus Vaccines |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Crimean-Congo hemorrhagic fever.
Next Document: The normal intestinal microbiota.